SCHEMBL5803267

SCHEMBL5803267

COc1cccc(OS(=O)(=O)c2cc(I)c3occc3c2)c1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
CA13 Q8N1Q1 1/20 0.38
MAOA P21397 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2A6 P11509 1/20 0.37
TSHR P16473 1/20 0.37
ACHE P22303 1/20 0.37
PDE4A P27815 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CYP2A13 Q16696 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5814581 0.81 HTR6 (0.40) CA1CA2CA9CYP3A4CYP1A2
SCHEMBL5804780 0.80 DRD2 (0.41)
SCHEMBL5803281 0.79 LMNA (0.39) CA2MAOACYP3A4CYP1A2CYP2D6
SCHEMBL5954926 0.76 MAPT (0.38) CA2ALDH1A1LMNAMEN1KMT2A
SCHEMBL5803260 0.75 HTR2C (0.41)
SCHEMBL5805845 0.75 HTR2C (0.41)
SCHEMBL31664216 0.71 ALDH1A1 (0.51) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL190382 0.71 ALDH1A1 (0.51) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL1060725 0.68 TP53 (0.51) TSHRMAPK1ALDH1A1LMNAMEN1
SCHEMBL1062600 0.68 CA1 (0.33) CA1CA2CA9MAOACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142269-A1 New compounds BIOVITRUM AB (SE) 2006-06-29 US disclosed
WO-2006062481-A1 NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . BIOVITRUM AB (SE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142269-A1 New compounds GPR119, GLP1R, IAPP CA1 2784/4885CA2 2927/4885CA9 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.